ClinicalTrials.gg
CompletedNCT00934375Updated Jan 14, 2014Results posted

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

A Phase 4 interventional study of Aricept (donepezil hydrochloride) and placebo in Mild Cognitive Impairment, sponsored by Eisai Inc.. Completed at 49 sites in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-01-14.

Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing donepezil in Cognitive Dysfunction — 1 open to participants now, 1 under way, none of them phase 3. Donepezil · Cognitive Dysfunction.

Enrollment
8th of 24
145 · median 70
Started
2006
the only one that year
Phase 4
8 of 25
none open now
Registered
10th of 25
by date
Lead sponsor
5 of 25
Eisai Inc.

Among the 25 studies testing donepezil in Cognitive Dysfunction, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2006, is one of 8 in phase 4, and was the 10th registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

1 of the 25 studies testing donepezil in Cognitive Dysfunction is open now. Recruiting first, the newest first:

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing donepezil in Cognitive Dysfunction, or all of them as a file.
02

Study summary

This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age Range: Adult subjects (45 to 90 years of age inclusive)
  2. Sex distribution: Men and women. Women of (\<1 year post menopausal) must be practicing effective and have negative serum B-HCG at Screening. [Women who are breast-feeding are excluded.]
  3. Subjects must have completed the one year, double-blind core trial (E2020-A001-412).
  4. A completed Diagnostic Worksheet at the end of the double-blind core trial (E2020-A001-412) indicating no conversion to Alzheimer's Disease or dementia.
  5. Health: Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane).
  6. The subject must be expected to complete the entire study.
  7. Subjects must be sufficiently fluent in English.
  8. Subjects must have an informant who has daily contact with the subject (e.g., an average of 10 or more hours per week), can observe for possible adverse events and will accompany the subject to all visits.
  9. Clinical laboratory values must be within normal limits, or if abnormal, judged clinically insignificant by the investigator (not likely to cause cognitive impairment or medical instability).

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have not completed or have terminated early from the one year, double-blind core trial (E2020-A001-412).
  2. Any subject without a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412).
  3. Any subject with a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412) indicating conversion to Alzheimer's or other dementia.
  4. Subjects with uncontrolled hypertension (sitting systolic >= 160mmHg and/or diastolic >=95mmHg) as assessed by the investigator, regardless of whether or not the subject is taking anti-hypertensive medications.
  5. Subjects with a history of malignant neoplasms treated within five years prior to study entry (other than basal or squamous cell carcinoma of the skin); current evidence of malignant neoplasm; or recurrent or matastatic disease.
  6. Subjects who have suffered a severe infection or a major surgical procedure within three months prior to baseline.
  7. Subjects who may not be able to comply with the protocol.
  8. Subjects with known to piperidine derivatives or acetylcholinesterase(AChE)inhibitors.
  9. Subjects with diabetes mellitis not controlled by diet and/or medication with a random serum glucose value of >170mg/dl.
  10. Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study.
  11. Subjects who do not have a reliable informant (e.g., the informant has contact with the subject less than 10 hours per week).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    1

    Drug: Aricept (donepezil hydrochloride)

  • Placebo comparator
    2

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs)

    Time frame: Baseline, Week 6, Week 12 and Week 28.

07

Results

Posted Jul 8, 2009

Participant flow

Participant flow — Overall Study
MilestoneDonepezilPlacebo
Started6877
Completed5555
Not completed1322

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs)

Time frame:
Baseline, Week 6, Week 12 and Week 28.
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsDonepezilPlacebo
Any Serious TEAE32
Any Severe TEAE23
Any possibly/probably drug-related TEAE1632
Any TEAE causing discontinuation of study drug.717

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil—3/68 (4.4%)11/68 (16.2%)
Placebo—2/77 (2.6%)20/77 (26%)
Most frequent serious events
Most frequent serious events
EventDonepezilPlacebo
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/680/77
Pelvic FractureInjury, poisoning and procedural complications1/680/77
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/681/77
OsteoarthritisMusculoskeletal and connective tissue disorders0/681/77
Most frequent other events
Most frequent other events
EventDonepezilPlacebo
DiarrheaGastrointestinal disorders4/6812/77
NauseaGastrointestinal disorders1/687/77
Muscle SpasmsMusculoskeletal and connective tissue disorders6/687/77
Abnormal dreamsPsychiatric disorders1/685/77
InsomniaPsychiatric disorders3/685/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)DonepezilPlaceboTotal
Mean71.7 ± 8.4673.4 ± 8.7372.6 ± 8.62
Sex: Female, Male
Sex: Female, Male(Participants)DonepezilPlaceboTotal
Female303666
Male384179
Region of Enrollment
Region of Enrollment(participants)DonepezilPlaceboTotal
United States6877145
08

Study locations

49 sites
  • Neurology Neurodiagnostic Lab, LLC
    Alabaster, Alabama 35007, United States
  • Pivotal Research Centers
    Peoria, Arizona 85381, United States
  • Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Northwest Neurospecialists, PLLC
    Tucson, Arizona 85741-3537, United States
  • The Neurology Center
    Encinitas, California 92024, United States
  • Margolin Brain Institute
    Fresno, California 93720, United States
  • Colaborative Neuroscience Network (CNS Network)
    Garden Grove, California 92845, United States
  • Nerve Pro Research
    Irvine, California 92618, United States
  • Optimum Health Services
    La Mesa, California 91942, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • CA Neuroscience Research
    Sherman Oaks, California 91403, United States
  • Pacific Research Network
    Vista, California 92081, United States
  • Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry
    New Haven, Connecticut 06510, United States
  • North Broward Medical Center Memory Disorder Center
    Deerfield Beach, Florida 33064, United States
  • Neurologic Consultants
    Ft. Lauderdale, Florida 33308, United States
  • Berma Research Group
    Hialeah, Florida 33016, United States
  • Sunrise Clinical Research
    Hollywood, Florida 33021, United States
  • Wien Center for Memory Disorders, Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Berma Research Group
    Plantation, Florida 33317, United States
  • The Roskamp Institute
    Sarasota, Florida 34243, United States
  • Comprehensive Neuroscience, Inc.
    St. Petersburg, Florida 33702, United States
  • Stedman Clinical Trials, LLC
    Tampa, Florida 33613, United States
  • USF Memory Disorder's Clinic
    Tampa, Florida 33613, United States
  • USF Suncoast Gerontalogy Center
    Tampa, Florida 33617, United States
  • Center for Clinical Trials. L.C.
    Venice, Florida 34285, United States
  • Palm Beach Neurology
    West Palm Beach, Florida 33407, United States
  • Lexington Clinic
    Lexington, Kentucky 40504, United States
  • Borgess Research Institute
    Kalamazoo, Michigan 49048, United States
  • St. Louis University - Clinical Trials Unit
    St. Louis, Missouri 63104, United States
  • Comprehensive Neuroscience, Inc
    Kenilworth, New Jersey 07033, United States
  • Neurological Associates of Albany, PC Neurology
    Albany, New York 12208, United States
  • Neurobehavioral Research Inc.
    Lawrence, New York 11559, United States
  • New York University School of Medicine Aging and Dementia Research Center
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Monroe Community Hospital Program in Neurobehavioral Therapeutics
    Rochester, New York 14620, United States
  • Behavioral Medical Research of Staten Island
    Staten Island, New York 10305, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Neurology Center of Ohio
    Toledo, Ohio 43623, United States
  • Pahl Pharmaceutical Research, LLC
    Oklahoma City, Oklahoma 73118, United States
  • Summit Research Network(Oregon) Inc.
    Portland, Oregon 97210, United States
  • Clinical Trial Specialists
    Bala Cynwyd, Pennsylvania 19004, United States
  • Westmoreland Neurology Associates
    Greensburg, Pennsylvania 15601, United States
  • The Clinical Trial Center, LLC
    Jenkintown, Pennsylvania 19046, United States
  • Medical University of South Carolina-Alzheimer's Research
    Charleston, South Carolina 29406, United States
  • The University of Texas Mental Sciences Instittute
    Houston, Texas 77030, United States
  • START Center
    San Antonio, Texas 78229-3900, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Southwestern Vermont Medical Center - The Memory Clinc
    Bennington, Vermont 05201, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2009
First posted
Jul 8, 2009
Start
Feb 2006
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results first posted
Jul 8, 2009
Last update
Jan 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00934375
Lead sponsor
Eisai Inc.
First posted
Jul 8, 2009
Start date
Feb 2006
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Jul 8, 2009
Last update
Jan 14, 2014

Study contacts

Anita Murthy
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion